Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.47 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19953927 | 1.00 | CRBN (0.47) | CRBNDDB1AVPR1BSCDALDH1A1 | |
| SCHEMBL19954314 | 1.00 | CRBN (0.47) | CRBNDDB1AVPR1BSCDALDH1A1 | |
| SCHEMBL23979421 | 0.95 | DDB1 (0.43) | CRBNDDB1AVPR1BSCDALDH1A1 | |
| SCHEMBL19953918 | 0.94 | CRBN (0.46) | CRBNDDB1AVPR1BALDH1A1LMNA | |
| SCHEMBL19953924 | 0.91 | CRBN (0.48) | CRBNDDB1SCDALDH1A1LMNA | |
| SCHEMBL19954310 | 0.91 | CRBN (0.48) | CRBNDDB1SCDALDH1A1LMNA | |
| SCHEMBL19953921 | 0.91 | CRBN (0.48) | CRBNDDB1SCDALDH1A1LMNA | |
| SCHEMBL19953932 | 0.90 | CRBN (0.50) | CRBNDDB1ALDH1A1LMNAKDM4E | |
| SCHEMBL19954299 | 0.90 | CRBN (0.50) | CRBNDDB1ALDH1A1LMNAKDM4E | |
| SCHEMBL19953928 | 0.90 | CRBN (0.50) | CRBNDDB1ALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277539-A1 | 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX LLC (US) | 2023-09-07 | — | — | US | disclosed |
| US-9913845-B2 | 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same | DEUTERX, LLC (US) | 2018-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277539-A1 | 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | AQP3, AQP4, AQP1 | CRBN 2849/4885DDB1 3771/4885AVPR1B 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.